The Society for Cardiac Angiography and Interventions (SCAI) has extended the abstract deadline for its 30th Annual Scientific Sessions in Orlando, May 9-12, 2007. The new deadline is December 22, 2006 at midnight (EST).

The top three abstracts will received awards, and the top 10 abstracts selected will be featured for oral presentantion. All accepted abstracts will be published in the May 2007 edition of SCAI's Journal, “Catheterization and Cardiovascular Interventions.”

CV Therapeutics has announced it will file a new drug application to the FDA for its regadenoson agent in mid-2007 following positive results from a late-stage trial, the Associated Press reported Monday.

Regadenoson is used in myocardial perfusion imaging studies, or studies on coronary artery disease. CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies.

Toronto-based Cedara Software, a Merge Healthcare company and an independent developer of medical software technologies for the global healthcare market, has announced a strategic partnership with Medical Imaging Applications LLC (MIA) of Coralville, Iowa. As part of the agreement, Cedara will distribute MIA’s vascular software applications to OEM companies through its global distribution network on an exclusive basis. MIA will focus on clinical development and continuing advancement of its toolset.

AngioDynamics, Inc. has announced FDA 510(k) clearance for Oncobionic, Inc. to market Irreversible Electroporation (IRE) — a technology approved for the surgical ablation of soft tissue, including cardiac and smooth muscle.

AngioDynamic’s acquisition of Oncobionic for a total of $25 million will be completed following successful human use of its IRE technology, testing that is expected to begin mid-year 2007.

Two novel polymer-free drug-eluting stent coating technologies tested in a comparative animal study has concluded with positive results, according to a release from Atlanta-based MIV Therapeutics.

Possis Medical, Inc. has received clearance from the FDA to market its AngioJet Xpeedior catheter to remove blood clots (thrombus) from upper- and lower-extremity peripheral veins. Used with the company’s AngioJet System, Xpeedior is the only device cleared for thrombectomy in peripheral veins.

Magnets may interfere with the operation of pacemakers and implantable cardioverter defibrillators (ICDs), according to a study published in the December 2006 edition of “Heart Rhythm.”

The Third International Conference on Cell Therapy for Cardiovascular Diseases will convene Jan 17 to 19, at The New York Academy of Medicine in New York, NY. The three-day program is dedicated to the evolving field of cell-based therapies for cardiac repair and regeneration.

The FDA has cleared Toshiba's new EXCELART Vantage Atlas 1.5T MRI system, which the company showcased this week during the annual meeting and exhibit of the Radiological Society of North America in Chicago.

GE Healthcare has launched its new LightSpeed VCT XT, the industry’s first CT scanner that maintains outstanding image quality while reducing a patient’s radiation exposure by up to 70 percent for diagnostic cardiac scans. The company unveiled the technology this week during the annual meeting of the Radiological Society of North America in Chicago.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now